Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular carcinoma
Phase 1
Recruiting
- Conditions
- unresectable hepatocellular carcinomaTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2022-500903-38-00
- Lead Sponsor
- niversity Hospital Grenoble
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method